Indivior PLC (INDV) Given New GBX 395 Price Target at Deutsche Bank AG
Indivior PLC (LON:INDV) had its target price dropped by equities research analysts at Deutsche Bank AG from GBX 400 ($5.22) to GBX 395 ($5.16) in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price objective would indicate a potential upside of 25.96% from the company’s current price.
Several other brokerages have also weighed in on INDV. Jefferies Group lifted their price target on Indivior PLC from GBX 330 ($4.31) to GBX 370 ($4.83) and gave the company a “buy” rating in a research note on Monday, August 22nd. Numis Securities Ltd restated a “buy” rating and issued a GBX 370 ($4.83) price target on shares of Indivior PLC in a research note on Monday, September 26th. Stifel Nicolaus restated a “buy” rating and issued a GBX 350 ($4.57) price target on shares of Indivior PLC in a research note on Wednesday, August 17th. Morgan Stanley lifted their price target on Indivior PLC from GBX 280 ($3.65) to GBX 330 ($4.31) and gave the company an “overweight” rating in a research note on Monday, August 1st. Finally, Royal Bank Of Canada lifted their price target on Indivior PLC from GBX 185 ($2.41) to GBX 325 ($4.24) and gave the company a “sector performer” rating in a research note on Tuesday, August 9th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of GBX 345.71 ($4.51).
Shares of Indivior PLC (LON:INDV) opened at 313.60 on Tuesday. Indivior PLC has a one year low of GBX 126.60 and a one year high of GBX 365.00. The stock’s market capitalization is GBX 2.26 billion. The stock has a 50 day moving average price of GBX 318.51 and a 200 day moving average price of GBX 236.26.
Indivior PLC Company Profile
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.
Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.